Uncategorized

New Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meeting

by Business Wire • 2019/10/24 • 0 Comments

DUBLIN--(BUSINESS WIRE)--Horizon today announced that clinical study data of teprotumumab for active thyroid eye disease (TED) will be presented during the ATA Annual Meeting.

Full Story →

← Aerie Pharmaceuticals Completes Enrollment in the Phase 2 Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion Ahead of Schedule

Lower eyelid retraction improved with dermal regeneration matrix template →

Post navigation